TABLE 2.
Infusion-related events in patients receiving amphotericin B in 5% dextrose (group 1) or in Intralipid (group 2)
| Event | Value for:
|
P | 95% CI | |
|---|---|---|---|---|
| Group 1 | Group 2 | |||
| Infusion-related fever | ||||
| No. of patients affected (%) | 28/33 (85) | 19/28 (68) | 0.11 | −4–38 |
| No. of associated administrations of amphotericin B (%) | 124/310 (40) | 58/252 (23) | <0.0001 | 9–24 |
| Median duration, days (range) | 2 (0–14) | 2 (0–7) | 0.07 | |
| Infusion-related rigors | ||||
| No. of associated administrations of amphotericin B (%) | 102/310 (33) | 15/252 (6) | <0.0001 | 21–33 |
| Median duration, days (range) | 2 (0–9) | 0 (0–3) | 0.004 | |
| Administration of meperidine | ||||
| No. of patients receiving (%) | 18/33 (54) | 6/28 (21) | 0.008 | 10–56 |
| No. of administrations of amphotericin B requiring drug (%) | 45/310 (14) | 8/252 (3) | <0.0001 | 7–16 |
| Hypotension, no. affected (%) | 3/33 (9) | 1/28 (4) | 0.62 | −6–17 |
| Hypokalemia, no. affected (%) | 19/33 (58) | 6/28 (21) | 0.004 | 13–59 |
| Nephrotoxicity, no. affected (%) | 7/22 (32) | 4/19 (21) | 0.44 | −16–37 |
| Difference between baseline and final concentrations of creatinine (mg/dl), mean | 0.36 | 0.26 | 0.5 | |